HIV/AIDS Clinical Trials in Los Angeles

Showing 361-380 of 648 trials

PHASES: Provision of HIV Treatment at ATN Sites: An Evaluation for Stakeholders

NCT02438592

This is an observational study involving retrospective and prospective medical record review covering a total maximum of 104 weeks (24 months) per subject. An Audio Computer- Assisted Self-Interview (ACASI) at study entry will assess demographic and psychosocial variables of study subjects. Data will also be collected to assess clinic level variables. Definitions of engagement, prescription of antiretroviral therapy (ART), and viral suppression in the Continuum of Care (CoC) will utilize common definitions including those by U.S. Department of Health and Human Services (DHHS) and Health Resources and Services Administration (HRSA) HIV/AIDS Bureau (HAB). Data will be collected in a large, simple trial design manner to provide all elements for both the primary and secondary outcomes.

HIV

University of North Carolina, Chapel Hill924 participantsStarted Mar 2015

Aurora, California, United States • Los Angeles, California, United States • Washington D.C., District of Columbia, United States +11 more locations

COMPLETED< 1 mile

Treatment De-Intensification and Residual HIV-1 in Youth

NCT00867854

This laboratory-based sub-study of ATN 061 and ATN 071 will examine the effect of early treatment followed by treatment de-intensification to atazanavir/ritonavir (ATV/r) monotherapy on steady-state frequencies of replication-competent CD4+ T cell Human Immunodeficiency Virus (HIV)-1 reservoirs or cell-associated infectivity (CAI) and persistent low-level viremia (LLV), and their contribution to successful long-term control of HIV-1 replication among HIV-1 infected adolescents and young adults.

HIV-1HIV Infections

University of North Carolina, Chapel Hill34 participantsStarted Feb 2009

Los Angeles, California, United States • San Francisco, California, United States • Washington D.C., District of Columbia, United States +14 more locations

PHASES: Provision of HIV Treatment at ATN Sites: An Evaluation for Stakeholders

Treatment De-Intensification and Residual HIV-1 in Youth

HIV/AIDS Trials in Other Cities

Immunologic Memory (Supp. of ATN 024)

Hepatitis B Vaccine Genetics: A Substudy of ATN 024 and ATN 025

Identifying Undiagnosed Asymptomatic HIV Infection in Hispanic/Latino Adolescents and Young Adults

Assessing the Engagement of Transgender and Other Gender Minority Youth Across the HIV Continuum of Care

HIV Treatment-Readiness Measure (HTRM) Validation

Immunogenicity Study of Vacc-4x Versus Placebo in Patients Infected With HIV

Hepatitis B Virus (HBV) Prevention for Homeless at Risk for HBV/Hepatitis C Virus (HCV)/HIV

Tipranavir Expanded Access Program (EAP) in PI-experienced Patients With HIV-1 Infection

An HIV Intervention for Black Men at Risk - The Enhanced Sexual Health Intervention for Men (ES-HIM)

A Study of HIV in Newly Infected Individuals

A Study Comparing the Efficacy and Safety of Once-Daily Fuzeon (Enfuvirtide) Dosing Versus the Currently Recommended Twice-Daily Dosing in Human Immunodeficiency Virus-Type 1 (HIV-1) Infected Patients

Factors Affecting Patient Participation in AIDS Malignancy Clinical Trials Consortium Clinical Trials

BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1.

Expanded Access Program for Maraviroc At Multiple Centers

Safety of EVG+RTV Administered With Other Antiretroviral Agents for the Treatment of HIV-1 Infection

The Effect of Acyclovir Treatment of the Herpes Simplex Virus (HSV) Infection on HIV Levels in the Blood

Adding Maraviroc to the HAART Regimen of Well Controlled HIV-infected Patients

An Open Label Safety Study of Tipranavir Co-administered With Low-dose Ritonavir in Patients With Advanced HIV-1 Infection and Limited Treatment Options.

Other Conditions in Los Angeles